Kenvue bounces as Trump's Tylenol-autism link not backed by new scientific evidence
** Shares of consumer health company Kenvue KVUE.N rise 6% to $17.99 premarket
** Stock hit record low on Monday after President Donald Trump linked autism to childhood vaccine use and taking co's pain medication Tylenol by women when pregnant
** Canaccord Genuity analysts say KVUE's risk is minimal and sell-off appears overblown, adding there is "more noise than substance"
** Citi analysts say they expected the stock to recover, citing absence of new scientific evidence from the White House briefing
** It is likely low-single-digit percentage of Tylenol sales come from use by pregnant women - Canaccord Genuity
** On September 5, the Wall Street Journal reported that Health Secretary Robert F. Kennedy Jr. planned to link Tylenol to autism
** Up to last close, stock fell 20.5% YTD
Related Articles
Micron Technology Q4 FY2025 Earnings Preview: Leveraging DRAM Strength and Accelerating HBM Growth
TradingKey - Micron Technology, Inc. (NASDAQ: MU) will report Q4 FY2025 results after the market close on Tuesday, September 23, 2025, with the webcasted conference call scheduled for 4:30 PM EDT. As a leading global supplier of memory chips, including DRAM, NAND flash, and advanced memory like...
Fed Rate Cuts: Will the Russell 2000 Outperform the S&P 500?
TradingKey - On 17 September, the Federal Reserve cut interest rates by 25 basis points, marking the official restart of the rate-cutting cycle. In theory, small-cap stocks, compared to large-cap stocks, benefit more from Fed rate cuts. This is because they are more reliant on external financing...
From Ozempic to Wegovy: Growth and Risks Behind Novo Nordisk’s Q2 Performance
TradingKey - Novo Nordisk achieved revenue of $11.67 billion in Q2 of the 2025 fiscal year, a 19% increase year-over-year, but it fell short of market expectations. Growth was primarily driven by strong performance in obesity care and rare diseases.
Bitcoin Price Forecast: Trends and Investment Outlook from 2025 to 2030
From $0.01 in 2009 to $120,000+ in 2025, Bitcoin has evolved from obscurity to a globally recognized financial asset. While institutions and governments increasingly embrace it, investors must remain vigilant against volatility, security risks, and scams.
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.
